查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370943

子宫肌瘤治疗药物市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类别、类型、最终用户、地区、竞争细分

Uterine Fibroid Treatment Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Type, By End User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 171 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年，全球子宫肌瘤治疗药物市场估值达到44.2亿美元，预计在预测期内大幅成长，预计复合年增长率（CAGR）为4.43%，到2028年预计将达到57.1亿美元。这种成长是由重塑市场格局的几个关键因素所推动的。

主要市场驱动因素

1. 子宫肌瘤盛行率增加

市场概况
预测期 2024-2028
2022 年市场规模 44.2亿美元
2028 年市场规模 57.1亿美元
2023-2028 年复合年增长率 4.43%
成长最快的细分市场 促性腺激素释放激素激动剂
最大的市场 北美洲

子宫肌瘤是生长在子宫内的良性肿瘤，已成为全球女性的重大健康议题。子宫肌瘤的盛行率正在上升，促使医疗保健专业人员、研究人员和政策制定者了解其影响因素。子宫肌瘤，也称为平滑肌瘤，是在子宫肌肉组织中形成的非癌性生长。它们在孕龄期尤其常见，可能会导致月经大量出血、骨盆腔疼痛和邻近器官受压等症状。近几十年来，子宫肌瘤的盛行率在全球范围内稳步上升。这一趋势是由多种因素复杂的相互作用所驱动的，包括生活方式、饮食习惯、体力活动水平的变化、延迟分娩、荷尔蒙波动和遗传因素。了解这种增加背后的原因对于解决子宫肌瘤日益增加的负担和开发有效的治疗方案至关重要。

2. 改变治疗模式

子宫切除术和子宫肌瘤切除术等传统外科手术历来是子宫肌瘤的主要治疗方法。然而，随着创新药物疗法的兴起，治疗范式发生了显着转变。这种转变是由于对微创治疗方案的渴望所推动的，这些治疗方案可以保留生育能力、提供更快的恢復时间并最大限度地降低与手术相关的风险。子宫肌瘤治疗药物，也称为药物疗法，已成为手术的可行替代方案。这些药物透过调节影响肌瘤生长的荷尔蒙、减轻症状并减少侵入性手术的需要来发挥作用。这种治疗方法的转变正在改善患者的治疗效果，并扩大了治疗子宫肌瘤的女性的选择范围。

3.良好的监管环境

监管环境在塑造新医疗方法的可用性和可及性方面发挥关键作用。子宫肌瘤治疗药物市场受益于鼓励创新和引入新疗法的有利监管环境。监管机构优先考虑子宫肌瘤等对女性健康有重大影响的疾病。为满足未满足的医疗需求的药物授予快速审查途径，从而加快其开发和审批流程。致力于妇女健康的患者权益团体和组织在提高人们对子宫肌瘤的认识和倡导改进治疗方案方面也发挥了至关重要的作用。这种有利的监管环境不仅透过及时提供创新疗法使患者受益，而且还激励製药公司投资研发。

主要市场挑战

1. 功效和长期数据

虽然子宫肌瘤治疗药物在缓解症状方面显示出希望，但对其长期疗效和安全性的质疑仍然存在。临床试验的观察期通常相对较短，因此很难充分了解这些药物的长期效果。产生可靠的长期资料对于确保患者的健康和对这些治疗的信心至关重要。

2. 患者的变异性

子宫肌瘤在大小、位置和患者概况方面表现出相当大的变异性。开发有效针对这种异质性的药物是一项重大挑战。个人化医疗方法正在受到关注，但针对个别患者量身定制治疗仍然很复杂，可能需要精准医疗的进一步进步。

3. 副作用和耐受性

与任何医疗介入一样，子宫肌瘤治疗药物也可能有副作用。平衡症状缓解与潜在不良反应是一项微妙的任务。实现适当的平衡以提供有意义的益处而不引起过度不适对于患者接受和坚持至关重要。

主要市场趋势

1. 联合疗法

将子宫肌瘤治疗药物与其他干预措施（例如微创手术或荷尔蒙疗法）相结合具有巨大的前景。这些协同方法旨在提供全面的解决方案，从多个角度针对肌瘤，优化症状缓解和长期结果。联合疗法可以为具有不同肌瘤特征的患者提供量身定制的治疗方法，从而提高护理的整体效果。

2. 注重生活品质

除了医疗功效之外，未来的趋势还强调提高患者的生活品质。子宫肌瘤治疗药物不仅可以缓解症状，还可以改善整体健康，将是最重要的。製药公司正在探索满足更广泛患者需求的疗法，并认识到子宫肌瘤对身体、情绪和社会生活的整体影响。

3. 非荷尔蒙治疗选择

虽然荷尔蒙疗法一直是子宫肌瘤治疗的支柱，但非荷尔蒙疗法也越来越受欢迎。目前正在探索针对参与肌瘤生长的特定细胞途径而不影响荷尔蒙水平的新药物。这些非荷尔蒙治疗可能为不适合荷尔蒙介入的患者提供替代方案。

细分市场洞察

类型洞察

2022年，黏膜下肌瘤主导全球子宫肌瘤治疗药物市场。黏膜下肌瘤是良性子宫生长物，通常在育龄期出现。然而，从 2023 年到 2030 年，壁内肌瘤类别预计将经历最高的年复合成长率(CAGR)。

最终用户行业洞察

零售药局领域在 2022 年占据市场主导地位，预计将继续扩大。零售药局广泛提供子宫肌瘤治疗的药物，包括非处方止痛药、口服药物和 GnRH 拮抗剂。该细分市场的成长是由患者对安全有效的治疗选择的需求所推动的。

区域洞察

由于肌瘤患病率上升、肌瘤引起的妊娠併发症以及新治疗方案的批准，北美引领全球子宫肌瘤治疗药物市场。该地区的医疗保健格局也受到肌瘤高发生率的影响，高达80% 的黑人女性和高达70% 的白人女性在50 岁之前患有肌瘤。人们对肌瘤的认识不断提高，治疗方案不断扩大，预计将推动北美市场进一步成长。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究应用分類的管道细分
  • 按地区分類的管道明细
  • 临床试验热图

第 6 章：全球子宫肌瘤治疗药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类别（促性腺激素释放激素 (Gnrh) 激动剂、促性腺激素释放激素 (Gnrh) 拮抗剂、黄体素释放子宫内避孕器 (Iud) 和避孕药、非荷尔蒙药物、其他）
    • 依类型（浆膜下肌瘤、壁内肌瘤、黏膜下肌瘤、带蒂肌瘤）
    • 按最终用户（医院药房、零售药房、其他）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图
    • 按药物类别
    • 按类型
    • 按最终用户
    • 按地区

第 7 章：北美子宫肌瘤治疗药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类别（促性腺激素释放激素 (Gnrh) 激动剂、促性腺激素释放激素 (Gnrh) 拮抗剂、黄体素释放子宫内避孕器 (Iud) 和避孕药、非荷尔蒙药物、其他）
    • 依类型（浆膜下肌瘤、壁内肌瘤、黏膜下肌瘤、带蒂肌瘤）
    • 按最终用户（医院药房、零售药房、其他）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 8 章：欧洲子宫肌瘤治疗药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类别（促性腺激素释放激素 (Gnrh) 激动剂、促性腺激素释放激素 (Gnrh) 拮抗剂、黄体素释放子宫内避孕器 (Iud) 和避孕药、非荷尔蒙药物、其他）
    • 依类型（浆膜下肌瘤、壁内肌瘤、黏膜下肌瘤、带蒂肌瘤）
    • 按最终用户（医院药房、零售药房、其他）
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 9 章：亚太子宫肌瘤治疗药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类别（促性腺激素释放激素 (Gnrh) 激动剂、促性腺激素释放激素 (Gnrh) 拮抗剂、黄体素释放子宫内避孕器 (Iud) 和避孕药、非荷尔蒙药物、其他）
    • 依类型（浆膜下肌瘤、壁内肌瘤、黏膜下肌瘤、带蒂肌瘤）
    • 按最终用户（医院药房、零售药房、其他）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 10 章：南美子宫肌瘤治疗药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类别（促性腺激素释放激素 (Gnrh) 激动剂、促性腺激素释放激素 (Gnrh) 拮抗剂、黄体素释放子宫内避孕器 (Iud) 和避孕药、非荷尔蒙药物、其他）
    • 依类型（浆膜下肌瘤、壁内肌瘤、黏膜下肌瘤、带蒂肌瘤）
    • 按最终用户（医院药房、零售药房、其他）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章：中东和非洲子宫肌瘤治疗药物市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类别（促性腺激素释放激素 (Gnrh) 激动剂、促性腺激素释放激素 (Gnrh) 拮抗剂、黄体素释放子宫内避孕器 (Iud) 和避孕药、非荷尔蒙药物、其他）
    • 依类型（浆膜下肌瘤、壁内肌瘤、黏膜下肌瘤、带蒂肌瘤）
    • 按最终用户（医院药房、零售药房、其他）
    • 按国家/地区
  • MEA：国家分析
    • 南非子宫肌瘤治疗药物
    • 沙乌地阿拉伯子宫肌瘤治疗药物
    • 阿联酋子宫肌瘤治疗药物
    • 科威特子宫肌瘤治疗药物

第 12 章：市场动态

  • 司机
  • 挑战

第 13 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 14 章：政策与监管环境

第 15 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第16章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Myovant Sciences Ltd
    • Pfizer Inc
    • Abbvie Inc
    • Ferring BV
    • AstraZeneca Pharmaceuticals LP
    • Bayer AG
    • Amring Pharmaceuticals Inc
    • Watson Pharma Pvt Ltd

第 17 章：策略建议

第 18 章：关于我们与免责声明

简介目录
Product Code: 17232

The Global Uterine Fibroid Treatment Drugs Market reached a valuation of USD 4.42 Billion in 2022 and is poised for substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 4.43% and expected to reach USD 5.71 Billion through 2028. This growth is driven by several key factors reshaping the market landscape.

Key Market Drivers

1. Increasing Prevalence of Uterine Fibroids

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.42 Billion
Market Size 2028USD 5.71 Billion
CAGR 2023-20284.43%
Fastest Growing SegmentGonaditropin releasing hormone ag0nists
Largest MarketNorth America

Uterine fibroids, which are benign tumors growing in the uterus, have become a significant global health concern for women. The prevalence of uterine fibroids is on the rise, prompting healthcare professionals, researchers, and policymakers to understand the contributing factors. Uterine fibroids, also known as leiomyomas, are non-cancerous growths that develop in the muscle tissue of the uterus. They are particularly common during the reproductive years and can cause symptoms like heavy menstrual bleeding, pelvic pain, and pressure on adjacent organs. In recent decades, the prevalence of uterine fibroids has steadily increased worldwide. This trend is driven by a complex interplay of factors, including changes in lifestyle, dietary habits, physical activity levels, delayed childbirth, hormonal fluctuations, and genetic factors. Understanding the reasons behind this increase is crucial for addressing the growing burden of uterine fibroids and developing effective treatment options.

2. Shifting Treatment Paradigms

Traditional surgical interventions such as hysterectomy and myomectomy have historically been the primary treatments for uterine fibroids. However, there is a notable shift in treatment paradigms as innovative pharmaceutical therapies gain prominence. This shift is driven by the desire for less invasive treatment options that preserve fertility, offer quicker recovery times, and minimize risks associated with surgery. Uterine fibroid treatment drugs, also known as pharmaceutical therapies, have emerged as viable alternatives to surgery. These drugs work by regulating hormones that influence fibroid growth, reducing symptoms, and decreasing the need for invasive procedures. This transformation in treatment approaches is improving patient outcomes and expanding the range of options available to women dealing with uterine fibroids.

3. Favorable Regulatory Environment

The regulatory landscape plays a pivotal role in shaping the availability and accessibility of new medical treatments. The uterine fibroid treatment drugs market benefits from a favorable regulatory environment that encourages innovation and the introduction of novel therapies. Regulatory agencies prioritize conditions like uterine fibroids, which have a significant impact on women's health. Expedited review pathways are granted to drugs addressing unmet medical needs, speeding up their development and approval processes. Patient advocacy groups and organizations dedicated to women's health have also played a crucial role in raising awareness about uterine fibroids and advocating for improved treatment options. This favorable regulatory environment not only benefits patients by providing timely access to innovative therapies but also incentivizes pharmaceutical companies to invest in research and development.

Key Market Challenges

1. Efficacy and Long-Term Data

While uterine fibroid treatment drugs show promise in alleviating symptoms, questions about their long-term efficacy and safety persist. Clinical trials often have relatively short observation periods, making it challenging to fully understand the long-term effects of these drugs. Generating robust long-term data is crucial to ensure patient well-being and confidence in these treatments.

2. Patient Variability

Uterine fibroids exhibit considerable variability in terms of size, location, and patient profiles. Developing drugs that effectively target this heterogeneity is a significant challenge. Personalized medicine approaches are gaining traction, but tailoring treatments to individual patients remains complex and may require further advancements in precision medicine.

3. Side Effects and Tolerability

Like any medical intervention, uterine fibroid treatment drugs can have side effects. Balancing symptom relief with potential adverse effects is a delicate task. Achieving the right balance to provide meaningful benefits without causing undue discomfort is essential for patient acceptance and adherence.

Key Market Trends

1. Combination Therapies

Combining uterine fibroid treatment drugs with other interventions, such as minimally invasive procedures or hormonal therapies, holds immense promise. These synergistic approaches aim to provide comprehensive solutions that target fibroids from multiple angles, optimizing symptom relief and long-term outcomes. Combination therapies can offer tailored treatments for patients with varying fibroid characteristics, enhancing the overall effectiveness of care.

2. Focus on Quality of Life

Beyond medical efficacy, future trends emphasize enhancing patients' quality of life. Uterine fibroid treatment drugs that not only alleviate symptoms but also improve overall well-being will be at the forefront. Pharmaceutical companies are exploring therapies that address a broader spectrum of patient needs, acknowledging the holistic impact of uterine fibroids on physical, emotional, and social aspects of life.

3. Non-Hormonal Treatment Options

While hormonal therapies have been a mainstay in uterine fibroid treatment, non-hormonal options are gaining traction. New drugs that target specific cellular pathways involved in fibroid growth, without affecting hormone levels, are being explored. These non-hormonal treatments may offer alternatives for patients who are not suitable candidates for hormonal interventions.

Segmental Insights

Type Insights

In 2022, submucosal fibroids dominated the global uterine fibroid treatment drugs market. Submucosal fibroids are benign uterine growths that often manifest during reproductive years. However, the intramural fibroids category is expected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030. Intramural fibroids

are known to drastically affect fertility outcomes, making their treatment a priority.

End User Industry Insights

The retail pharmacies segment dominated the market in 2022 and is expected to continue expanding. Retail pharmacies offer widespread availability of pharmaceuticals used in uterine fibroid treatment, including over-the-counter pain drugs, oral treatments, and GnRH antagonists. This segment's growth is driven by the demand for safe and efficient treatment choices among patients.

Regional Insights

North America leads the global uterine fibroid treatment drugs market due to the rising prevalence of fibroids, pregnancy complications caused by fibroids, and the approval of new treatment options. The region's healthcare landscape is also influenced by the high incidence of fibroids, with up to 80% of Black women and up to 70% of White women experiencing fibroids by the age of 50. The increasing awareness of fibroids and expanding treatment options are expected to fuel further market growth in North America.

Key Market Players

  • Myovant Sciences Ltd
  • Pfizer Inc
  • Abbvie Inc
  • Ferring BV
  • AstraZeneca Pharmaceuticals LP
  • Bayer AG
  • Amring Pharmaceuticals Inc
  • Watson Pharma Pvt Ltd

Report Scope:

In this report, the Global Uterine Fibroid Treatment Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Uterine Fibroid Treatment Drugs Market, By Drug Class:

  • Gonadotropin-Releasing Hormone (Gnrh) Agonists
  • Gonadotropin-Releasing Hormone (Gnrh) Antagonists
  • Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
  • Non-Hormonal Medications
  • Others

Uterine Fibroid Treatment Drugs Market, By Type:

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

Uterine Fibroid Treatment Drugs Market, By End User:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Uterine Fibroid Treatment Drugs Market, By region:

  • North America
  • United States
  • Mexico
  • Canada
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Uterine Fibroid Treatment Drugs Market.

Available Customizations:

  • Global Uterine Fibroid Treatment Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Uterine Fibroid Treatment Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 6.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 6.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Product Market Map
    • 6.3.1. By Drug Class
    • 6.3.2. By Type
    • 6.3.3. By End User
    • 6.3.4. By Region

7. North America Uterine Fibroid Treatment Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 7.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 7.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Mexico Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Canada Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User

8. Europe Uterine Fibroid Treatment Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 8.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 8.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. Asia-Pacific Uterine Fibroid Treatment Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 9.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 9.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. India Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Korea Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User
    • 9.3.4. Japan Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Type
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Type
        • 9.3.5.2.3. By End User

10. South America Uterine Fibroid Treatment Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 10.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 10.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Middle East and Africa Uterine Fibroid Treatment Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 11.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 11.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Type
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Type
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Type
        • 11.3.3.2.3. By End User
    • 11.3.4. Kuwait Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Drug Class
        • 11.3.4.2.2. By Type
        • 11.3.4.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Policy & Regulatory Landscape

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Company Snapshot
  • 16.3. Products & Services
  • 16.4. Financials (In case of listed companies)
  • 16.5. Recent Developments
  • 16.6. SWOT Analysis
    • 16.6.1. Myovant Sciences Ltd
    • 16.6.2. Pfizer Inc
    • 16.6.3. Abbvie Inc
    • 16.6.4. Ferring BV
    • 16.6.5. AstraZeneca Pharmaceuticals LP
    • 16.6.6. Bayer AG
    • 16.6.7. Amring Pharmaceuticals Inc
    • 16.6.8. Watson Pharma Pvt Ltd

17. Strategic Recommendations

18. About Us & Disclaimer